As we make our way through the first quarter of 2017, there are a lot of exciting changes happening in the field of health economics and outcomes research (HEOR) that may have important implications for how researchers generate and disseminate evidence.

Here are some of them, in no particular order, with commentaries to follow over the coming days and weeks:

  • Panel on Cost-Effectiveness in Health Care: The long-waited 20th anniversary of the original Gold Report now includes two perspectives: societal and healthcare system. It also includes additional documentation in the form of checklists and inventories.
  • 21st Century Cures Act: New legislative update to FDAMA 114, that expands the use of real-world evidence in the development of dossiers and, potentially, drug labelling.

These major updates and changes should keep the HEOR community busy throughout 2017 and beyond, creating new economic models and expanding the array of observational database studies performed.  There is no better time to be an health economics outcomes researcher!

Joe Menzin, PhD

Joseph Menzin, Ph.D. is the CEO of BHE, a health analytics research firm that he founded in 1996. He has more than 30 years of experience in the fields of outcomes research, epidemiology, and informatics. Joe spearheaded the development and launch of BHE’s flagship analytics platforms. He has authored several dozen papers in medical, pharmacy, and outcomes research journals across a wide range of subjects from clinical trials to program evaluation. He serves as a reviewer for numerous journals, and is a member of many professional associations. Joe has a Bachelor’s degree in Economics from the University of Rochester and earned his doctorate in Economics from Boston University.

Comments are closed.